PT1760089E - Peptídeos associados a tumores que se ligam a moléculas de classe i ou ii do antigénio leucocitário humano (hla) e correspondente vacina anti-cancerígena - Google Patents

Peptídeos associados a tumores que se ligam a moléculas de classe i ou ii do antigénio leucocitário humano (hla) e correspondente vacina anti-cancerígena Download PDF

Info

Publication number
PT1760089E
PT1760089E PT05019255T PT05019255T PT1760089E PT 1760089 E PT1760089 E PT 1760089E PT 05019255 T PT05019255 T PT 05019255T PT 05019255 T PT05019255 T PT 05019255T PT 1760089 E PT1760089 E PT 1760089E
Authority
PT
Portugal
Prior art keywords
molecules
tumour
present
relates
hla
Prior art date
Application number
PT05019255T
Other languages
English (en)
Portuguese (pt)
Inventor
Harpreet Singh
Niels Emmerich
Steffen Walter
Toni Weinschenk
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of PT1760089E publication Critical patent/PT1760089E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT05019255T 2005-09-05 2005-09-05 Peptídeos associados a tumores que se ligam a moléculas de classe i ou ii do antigénio leucocitário humano (hla) e correspondente vacina anti-cancerígena PT1760089E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05019255A EP1760089B1 (en) 2005-09-05 2005-09-05 Tumor-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules and related anti-cancer vaccine

Publications (1)

Publication Number Publication Date
PT1760089E true PT1760089E (pt) 2009-10-19

Family

ID=35149455

Family Applications (2)

Application Number Title Priority Date Filing Date
PT05019255T PT1760089E (pt) 2005-09-05 2005-09-05 Peptídeos associados a tumores que se ligam a moléculas de classe i ou ii do antigénio leucocitário humano (hla) e correspondente vacina anti-cancerígena
PT06777167T PT1922334E (pt) 2005-09-05 2006-09-05 Peptídeos associados a tumores que se ligam a moléculas de classe i ou ii do antigénio leucocitário humano (hla) e correspondente vacina anti-cancerígena

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT06777167T PT1922334E (pt) 2005-09-05 2006-09-05 Peptídeos associados a tumores que se ligam a moléculas de classe i ou ii do antigénio leucocitário humano (hla) e correspondente vacina anti-cancerígena

Country Status (23)

Country Link
US (1) US20090274714A1 (https=)
EP (2) EP1760089B1 (https=)
JP (1) JP5132561B2 (https=)
KR (1) KR101150663B1 (https=)
CN (1) CN101287755B (https=)
AT (2) ATE440107T1 (https=)
AU (1) AU2006289289B2 (https=)
BR (1) BRPI0615466A2 (https=)
CA (1) CA2621414C (https=)
CY (2) CY1110536T1 (https=)
DE (2) DE602005016112D1 (https=)
DK (2) DK1760089T3 (https=)
EA (1) EA013466B1 (https=)
ES (2) ES2330013T3 (https=)
HR (1) HRP20110240T1 (https=)
NO (1) NO20081690L (https=)
NZ (1) NZ565956A (https=)
PL (2) PL1760089T3 (https=)
PT (2) PT1760089E (https=)
RS (1) RS51893B (https=)
SI (2) SI1760089T1 (https=)
UA (2) UA97095C2 (https=)
WO (1) WO2007028573A1 (https=)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1806358T1 (sl) 2005-09-05 2010-06-30 Immatics Biotechnologies Gmbh S tumorjem povezani peptidi ki se promiskuitetnovežejo na molekule humanega levkocitnega antigena HLA razreda II
US20090004213A1 (en) 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
ES2321680B1 (es) * 2007-04-26 2010-03-05 Fundacion Para La Investigacion Biosanitaria De Andalucia Oriental - Alejandro Otero (Fibao) Restauracion de las moleculas hla de clase i mediante terapia genica empleando vectores adenovirales portando el gen de la beta 2-microglobulina.
CN103864893B (zh) * 2007-07-27 2017-01-04 伊玛提克斯生物技术有限公司 免疫疗法的免疫抗原表位
HUE032379T2 (en) * 2007-07-27 2017-09-28 Immatics Biotechnologies Gmbh Composition of tumour-associated peptides and related anti-cancer vaccine
HRP20150820T1 (xx) 2007-07-27 2015-09-11 Immatics Biotechnologies Gmbh Nova imunoterapija protiv neuronskih tumora i tumora mozga
CY1112212T1 (el) * 2008-04-24 2015-12-09 Immatics Biotechnologies Gmbh Νεα σκευασματα πεπτιδιων που σχετιζονται με ογκους τα οποια συνδεονται σε μορια του αντιγονου ανθρωπινων λευκοκυτταρων (hla) ταξης i ή ii για εμβολια
EP2113253B1 (en) * 2008-04-30 2010-03-31 Immatics Biotechnologies GmbH Novel formulations of tumour-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules for vaccines
ES2532896T5 (es) 2008-05-14 2018-03-20 Immatics Biotechnologies Gmbh Péptidos del MHC de clase II novedosos y potentes derivados de survivina y neurocan
AU2016204711B2 (en) * 2008-10-01 2018-03-01 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors including neuronal and brain tumors
RS53782B1 (sr) * 2008-10-01 2015-06-30 Immatics Biotechnologies Gmbh Preparati tumor-asociranih peptida i odgovarajuća antikancerska vakcina za tretman glioblastoma (gbm) i drugih kancera
GB201004551D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201004575D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
GB201006360D0 (en) * 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
GB201009222D0 (en) 2010-06-02 2010-07-21 Immatics Biotechnologies Gmbh Improved cancer therapy based on tumour associated antigens derived from cyclin D1
MY166516A (en) * 2010-12-02 2018-07-05 Oncotherapy Science Inc Tomm34 peptides and vaccines including the same
ES2647768T3 (es) * 2011-07-05 2017-12-26 Cadila Pharmaceuticals Limited Antígeno de cáncer
MY170949A (en) * 2011-07-11 2019-09-20 Cancer Res Initiatives Foundation A peptide capable of binding with a human leukocyte antigen (hla) molecule, a cancer vaccine derived from said peptide and use of said cancer vaccine
JP6464081B2 (ja) 2012-06-27 2019-02-06 ラトガース,ザ ステート ユニバーシティ オブ ニュー ジャージー フローサイトメトリーを用いたrna測定によるt細胞活性化のための迅速アッセイ
US20140017267A1 (en) * 2012-07-13 2014-01-16 Matthias W Rath Metalloproteinase oligopeptides and their therapeutic use
TWI636065B (zh) * 2013-08-05 2018-09-21 伊瑪提克斯生物科技有限公司 新穎肽類,細胞及其用於治療多種腫瘤的用途,其製造方法及包含其等之醫藥組成物
JP6781403B2 (ja) 2013-12-09 2020-11-04 タルゴバックス エーエスエー ペプチド混合物
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
MA49156A (fr) 2014-12-23 2020-03-25 Immatics Biotechnologies Gmbh Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
DK3271382T3 (da) * 2015-03-16 2020-05-04 Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft Fremgangsmåde til detektion af nye immunogene T-celleepitoper og isolering af nye antigenspecifikke T-cellereceptorer ved hjælp af et MHC-cellebibliotek
MY190083A (en) 2015-03-17 2022-03-25 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
GB201504502D0 (en) * 2015-03-17 2015-04-29 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
LT3388075T (lt) 2015-03-27 2023-11-10 Immatics Biotechnologies Gmbh Nauji peptidai ir peptidų deriniai, skirti naudoti imunoterapijai prieš įvairius navikus (seq id 25 - mrax5-003)
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
GB201505585D0 (en) 2015-03-31 2015-05-13 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
GB201507030D0 (en) * 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
TW202231659A (zh) 2015-06-19 2022-08-16 德商英麥提克生物技術股份有限公司 用於免疫治療的新穎胜肽及胜肽組合物與產生用於抗胰臟癌及其他癌症的支架的方法
GB201510771D0 (en) 2015-06-19 2015-08-05 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer
GB201511191D0 (en) 2015-06-25 2015-08-12 Immatics Biotechnologies Gmbh T-cell epitopes for the immunotherapy of myeloma
HK1254866A1 (zh) 2015-06-25 2019-07-26 Immatics Biotechnologies Gmbh 用於骨髓瘤和其他癌症免疫治疗的新型细胞表位和细胞表位组合物
GB201511546D0 (en) * 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
MA54884A (fr) 2015-07-01 2022-01-12 Immatics Biotechnologies Gmbh Neuartige peptide und kombination aus peptiden zur verwendung in der immuntherapie gegen ovarialkarzinom und andere karzinome
GB201511792D0 (en) * 2015-07-06 2015-08-19 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers
CR20230563A (es) * 2015-07-06 2024-01-22 Immatics Biotechnologies Gmbh NUEVOS PÉPTIDOS Y COMBINACIÓN DE PÉPTIDOS PARA USAR EN INMUNOTERAPIA CONTRA EL CÁNCER ESOFÁGICO Y OTROS CÁNCERES (Divisional Exp. 2017-0579)
MY189596A (en) * 2015-07-15 2022-02-18 Immatics Biotechnologies Gmbh A novel peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
GB201517538D0 (en) 2015-10-05 2015-11-18 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
PH12022551111A1 (en) 2015-10-05 2023-08-23 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
EP3167898A1 (en) 2015-11-11 2017-05-17 IEO - Istituto Europeo di Oncologia Srl Method for obtaining tumor peptides and uses thereof
US11464839B2 (en) * 2015-12-04 2022-10-11 Mayo Foundation For Medical Education And Research Methods and vaccines for inducing immune responses to multiple different MHC molecules
PE20230343A1 (es) 2015-12-11 2023-03-01 Immatics Biotechnologies Gmbh Peptidos que estimulan respuestas inmunitarias antitumorales
GB201521894D0 (en) * 2015-12-11 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers
JP2019512263A (ja) * 2016-02-22 2019-05-16 オーシャンサイド バイオテクノロジー 免疫療法におけるネオ抗原組成物及び同組成物を使用する方法
JP2019513373A (ja) * 2016-03-31 2019-05-30 ネオン セラピューティクス, インコーポレイテッド ネオ抗原およびその使用方法
TWI796299B (zh) * 2016-08-26 2023-03-21 德商英麥提克生物技術股份有限公司 用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
KR102379955B1 (ko) 2016-12-08 2022-03-29 이매틱스 바이오테크놀로지스 게엠베하 짝짓기가 향상된 t 세포 수용체
CN106986932A (zh) * 2017-04-06 2017-07-28 海口市人民医院 一种c‑Met表位肽及其应用
JP6857930B2 (ja) * 2018-02-15 2021-04-14 国立大学法人旭川医科大学 がん抗原ペプチド
CN110804642B (zh) * 2019-09-10 2022-06-21 清华大学 Gpr174免疫学功能及其用途
CN114641315A (zh) * 2019-11-14 2022-06-17 博阿济吉大学 癌症免疫疗法中的asc斑点
CN114524870A (zh) * 2020-11-23 2022-05-24 香雪生命科学技术(广东)有限公司 源自于ssx2抗原的短肽
US20240358808A1 (en) * 2021-04-23 2024-10-31 Flow Pharma, Inc. Vaccine for sars-cov-2
CN118620040A (zh) * 2022-01-05 2024-09-10 成都朗谷生物科技股份有限公司 一种针对乙型肝炎病毒的抗原肽

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
LU88258I2 (https=) 1978-12-22 1994-02-03
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
EP0671926B1 (en) * 1992-08-11 2002-11-13 President And Fellows Of Harvard College Immunomodulatory peptides
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
EP0769963A4 (en) 1994-07-27 1999-07-28 Commw Scient Ind Res Org POLYEPITOPE VACCINES
CA2243235C (en) 1996-01-17 2010-08-10 Imperial College Innovations Limited Immunotherapy using cytotoxic t lymphocytes (ctl)
US6096313A (en) * 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
US6316213B1 (en) * 1997-03-19 2001-11-13 The Board Of Trustees Of The University Of Arkansas Methods for the early diagnosis of ovarian, breast and lung cancer
IL125608A0 (en) * 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
DE19917195B4 (de) 1999-04-16 2006-09-28 Immatics Biotechnologies Gmbh Peptid zur Auslösung einer Immunreaktion gegen Tumorzellen, diese enthaltende pharmzeutische Zusammensetzungen, dessen Verwendungen, dafür codierende Nukleinsäure und diese Nukleinsäure enthaltender Expressionsvektor
KR100358068B1 (ko) * 1999-12-28 2002-10-25 주식회사 하이닉스반도체 플래쉬 메모리 소자의 제조방법
WO2004014867A2 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Matrix metalloproteinase inhibitors and methods for identification of lead compounds
US20060045881A1 (en) * 2004-08-26 2006-03-02 Board Of Regents, The University Of Texas System Anti-cancer vaccines

Also Published As

Publication number Publication date
ES2330013T3 (es) 2009-12-03
EA013466B1 (ru) 2010-04-30
HRP20110240T1 (en) 2011-05-31
BRPI0615466A2 (pt) 2011-05-17
PT1922334E (pt) 2011-04-01
EP1922334A1 (en) 2008-05-21
EP1760089B1 (en) 2009-08-19
AU2006289289A1 (en) 2007-03-15
UA105210C2 (ru) 2014-04-25
RS51893B (sr) 2012-02-29
EA200800676A1 (ru) 2008-08-29
PL1922334T3 (pl) 2011-06-30
CA2621414C (en) 2016-10-04
DK1760089T3 (da) 2009-11-16
WO2007028573A1 (en) 2007-03-15
EP1922334B1 (en) 2011-01-05
PL1760089T3 (pl) 2010-03-31
CY1110536T1 (el) 2015-04-29
SI1922334T1 (sl) 2011-04-29
ATE440107T1 (de) 2009-09-15
ATE494303T1 (de) 2011-01-15
JP2009506762A (ja) 2009-02-19
CN101287755B (zh) 2014-12-31
DE602005016112D1 (de) 2009-10-01
SI1760089T1 (sl) 2009-12-31
NO20081690L (no) 2008-04-04
NZ565956A (en) 2011-06-30
EP1760089A1 (en) 2007-03-07
JP5132561B2 (ja) 2013-01-30
DK1922334T3 (da) 2011-04-18
CY1113062T1 (el) 2016-04-13
KR101150663B1 (ko) 2012-05-25
CN101287755A (zh) 2008-10-15
CA2621414A1 (en) 2007-03-15
US20090274714A1 (en) 2009-11-05
ES2358802T3 (es) 2011-05-13
AU2006289289B2 (en) 2012-04-19
UA97095C2 (ru) 2012-01-10
KR20080052647A (ko) 2008-06-11
WO2007028573A9 (en) 2008-05-02
DE602006019446D1 (de) 2011-02-17

Similar Documents

Publication Publication Date Title
PL1922334T3 (pl) Peptydy towarzyszące nowotworom, wiążące się z cząsteczkami klasy I i II antygenów HLA i związana z nimi szczepionka przeciwnowotworowa
SI2135878T1 (sl) S tumorjem povezani peptidi ki se promiskuitetnovežejo na molekule človeškega levkocitnega antigena HLA Human Leukocyte Antigen razreda II
SI1794190T1 (sl) Imunogeni T-pomagalni epitopi iz humanih tumornih antigenov in imunoterapevtski postopki, ki uporabljajo navedene epitope